Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

J&J arthritis drug has mixed results against incumbents

Published 11/12/2016, 05:00 PM
Updated 11/12/2016, 05:00 PM
J&J arthritis drug has mixed results against incumbents
  • Johnson & Johnson (NYSE:JNJ) says experimental sirukumab treatment for rheumatoid arthritis showed mixed results against AbbVie (NYSE:ABBV) top-selling Humira in a large trial.
  • By one measure, patients with moderate to severe disease who took sirukumab showed significantly greater improvement in the Phase III study than those taking Humira. But another comparison showed no significant benefit of one drug over the other.
  • Results of the study were reported today at the annual meeting of the American College of Rheumatology in Washington.
  • Humira, and other older medicines such as Amgen (NASDAQ:AMGN) Enbrel and J&J's Remicade, works by blocking a protein called tumor necrosis factor ("TNF") that is involved in inflammation. Sirukumab is a member of an emerging new class of treatments that work instead by blocking IL-6, another protein involved in the inflammation process.
  • Source

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.